We're here today because healthcare is failing half of our population women. Currently we focus on outdated modes of acute care that are expensive versus preventative care, it's cheaper and has better outcomes. Obviously, status quo just isn't working. Women's Health is a massive market. So as you can see on the screen, there is money here to be made. And some specific examples. pcls associated care is around $2 billion. And the first thing that the first thing that prinos is working on gestational diabetes costs around $1.6 billion each year. So let's dive in a little bit into gestational diabetes. So around 13% of pregnant women are suffering from gestational diabetes, that number is rising each year. Currently, the standard of care for gestational diabetes is lacking way more than people even realize. So women drink this bottle of sugary grew after fasting for a few hours to diagnose gestational diabetes at 28 weeks, which is really too late for any preventative measures. And then women are offered printouts to manually track their glucose with minimal support, or really no insight. And brace yourself, the standard of care was developed in 1913. So really let that sink in 1913? What if there was a technologically advanced solution that lower costs and lead to better outcomes? Hey, spoiler alert, there is at premium, we created a women's health platform that utilizes genetic space diagnostics and social determinants of health to give a more comprehensive look at Whole Health for women. So genetic diagnostics that lack actionability really may as well be a BuzzFeed survey. These diagnostics are really overwhelming, there's no clear next steps, and they really fail to consider other things that impact health premium is building the next generation of at home testing that goes beyond just your genetics, we have an at home physician ordered kit. And all you have to do is really do a saliva sample, and then an online social determinants of health survey to give us the information we need. We then do a low pass home genome approach in our lab. And this information is then combined with those social determinants of health to generate accurate scores for each condition. So now let's take a look at the mind at premium app move to live demo.
So for screen one, as you can see, our customers receive an easy to read result the highlight service score here a patient can see their current risk score. And this is really where most genetic testing ins but we focus on driving outcomes. So as you can see, a patient can also see their goals score that is achieved by completing different interventions and making small lifestyle changes. On screen too. You can view the current risk score as it's changing over time depending on those interventions they're engaging with. This allows you to really meaningfully see where risk is and how it's changing. Obviously, again, our biggest feature is allowing customers to take action. So for screen three customers at risk for gestational diabetes can sync their continuous glucose monitor data. And we generate insights into food planning, food, timing and information on how to access what they need. Back to presentation. So, while at Johns Hopkins and the American College of Obstetricians and Gynecologists, I saw new technologies like genetics really being underutilized or basically non existent and women's health. And our team premium comes from the biggest companies in healthcare and tech, former leaders of the AMA experts in social determinants of health geneticists, some of the leading ob gyn in the country, we're all working to really use our expertise in the creation of groundbreaking technologies and women's health. And this is specifically for gender. for women's health, we really want genetics that are for the conditions that women are suffering from. And right now we're super proud to announce our preliminary data from our one in seven study, something really exciting has happened, we're able to accurately diagnose gestational diabetes at around 80%. This nasty Luca skew only really is around 70% accurate, and that's only for a short period of time. So we're really excited to already be beating the current standard of care, we're going to quickly move into endometriosis, uterine fibroids and postpartum depression. And we're also developing the largest biobank and women's health to help us with companion diagnostics, therapeutic identifications and other personalized medicine offerings. So we have really simple pricing, we believe that no subscription should cost more than what you pay for Netflix so so pay patients $300 per test, they can also pay through PG pay. Our companion app will be available for 1499 a month and we have fully reimbursable high touch interventions. So premium really truly is the missing link and the 108 billion dollar women's health market, we're really leading the way in new standards of care by predicting and preventing the conditions that are hugely problematic for women everywhere. And they cost payers and employers billions of dollars each year, we are building the next generation of women's health. And today we're opening our waitlist and our clinical study registry to the general public. So visit us@www.seannal.com or on Twitter at my prinos. Either yourself, your mother, your sister, your daughter, your wife, your friend, you should really should take advantage of this opportunity to really help us especially as we move into technologies that really let's let's let's be that link in the missing chain. So thank you so much.
GV, that was wonderful. And I love that logo. Lindy, let's start with you.
Thanks. That was exciting to hear about. Do you expect to do the customer acquisition in the initial on ramp up pregnancy?
Is that the the entry point for for customers to get engaged? Yeah, so actually, what we're doing is we're allowing women to do this at not only their eight week visit that initial prenatal visit, but also pre pregnancy. And since we are starting in gestational diabetes, that is something that can happen is your well woman visit but for some of our other conditions, like as we start to move into chronic conditions, we do want to make sure we're catching women, as soon as they really can start to make interventions in their life to change those risks. So no, we're not trying to get just the customers at that eight week prenatal visit.
Emily, first of all, I love you got to the presentation, not saying Zantac, because women's health is health care, 80% of the spend 51% of the market. So very excited that more of these companies have also consumed two of those jugs of goo and it's horrible, and there should be a different solution. My question is around go to market and just really clarifying. So it sounds like the test itself is not something that's reimbursed, you're doing that as out of pocket, there will be some clinical interventions that could be reimbursed. One, do you plan on pursuing a pathway where ultimately you'd look for these tests to be reimbursed into? Would you ever work in conjunction with their existing ob or other clinicians? Or is this something that would be a separate care pathway from your existing relationship?
